Every material Form 8-K Q32 Bio Inc. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Q32 Bio reported a third-quarter 2026 net loss of $8.9 million, or $0.26 per share, compared with $7.4 million, or $0.60 per share, a year earlier. The loss grew while per-share loss narrowed, as weighted-average shares rose to about 34.0 million from 12.2 million. The company also presented additional SIGNAL-AA Part B results and said it expects to start a registration-directed program in the first half of 2027, subject to regulatory discussions in the fourth quarter of 2026.
Net loss was $8.9 million for the quarter ended September 30, 2026, versus $7.4 million a year earlier.
Net loss per share was $0.26 versus $0.60, with weighted-average shares of 34,022,755 versus 12,240,542.
Cash and cash equivalents were $289.6 million at September 30, 2026, versus $48.3 million at December 31, 2025.
Research and development expenses were $5.1 million, up from $3.6 million, and general and administrative expenses were $5.5 million, up from $4.0 million.
Q32 Bio said on September 30, 2026 that additional 36-week results and initial 16-week off-drug findings from Part B of its open-label SIGNAL-AA Phase 2a trial of bempikibart were presented at the EADV Congress 2026. The Part B study enrolled 33 patients with severe or very severe alopecia areata, and the company plans to start a registration-directed program in the first half of 2027, subject to regulatory discussions in the second half of 2026.
At Week 36, mean SALT score reduction from baseline was 35.3% in the mITT analysis, and 40.0% (10/25) of mITT patients achieved a SALT-20 response.
At the 16-week off-drug time point, 44% of patients achieved SALT-20, 61% achieved SALT 30 and 50% achieved SALT 50 (18 patients entered this period).
The company reported no serious adverse events or Grade 3 or higher treatment-related adverse events; injection site reactions were the most common treatment-emergent adverse event at 36.3%.
Q32 Bio plans regulatory discussions in the second half of 2026, a registration-directed program in the first half of 2027, and expects Part B open-label extension data in the second half of 2027.
Q32 Bio named José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer on September 14, 2026. The company said the appointments come as it moves into a late clinical stage and prepares a registration-directed program for bempikibart in alopecia areata.
Trevejo was CMO at Enveda Therapeutics from July 2024 to September 2026 and earlier CMO at Tarsus Pharmaceuticals from February 2022 to February 2024.
Hershberger was Chief Development Officer at Adagio Therapeutics, now Invivyd, from June 2020 to January 2023.
Company plans to advance bempikibart into a registration-directed program in alopecia areata in the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Q32 Bio Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →